Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Adds To Biosimilars Capabilities Through Partnership With Lonza

This article was originally published in The Pink Sheet Daily

Executive Summary

Israeli generic giant, Swiss CMO announce joint venture to co-develop, manufacture and market biosimilars.

You may also be interested in...



Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.

Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics

U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.

Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics

U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel